Actavis announced that G. Frederick Wilkinson, president of Actavis Global R&D, will leave the company, effective April 25.
Mr. Wilkinson has accepted the position of president and CEO at Impax Laboratories. He was appointed president of Actavis Global R&D in January.
Actavis develops and manufactures pharmaceutical products. The company's North American branded pharmaceuticals business is focused primarily on women's health, urology, gastroenterology and dermatology.
AGA Calls for More Transparency From CMS
The Growing Role of Biologics in Gastroenterology
Mr. Wilkinson has accepted the position of president and CEO at Impax Laboratories. He was appointed president of Actavis Global R&D in January.
Actavis develops and manufactures pharmaceutical products. The company's North American branded pharmaceuticals business is focused primarily on women's health, urology, gastroenterology and dermatology.
More Articles on Gastroenterology:
9 Statistics on Gastroenterologist Compensation by LocationAGA Calls for More Transparency From CMS
The Growing Role of Biologics in Gastroenterology